CWM
TSHA icon

CIBC World Markets’s Taysha Gene Therapies TSHA Stock Holding History

CIBC World Markets’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$80.4K Buy
+14,612
New +$71K ﹤0.01% 1181
2025
Q2 		$47.2K Sell
20,417
-18,480
-48% -$40.1K ﹤0.01% 1480
2025
Q1 		$54.1K Buy
38,897
+22,492
+137% +$37.6K ﹤0.01% 1708
2024
Q4 		$28.4K Buy
+16,405
New +$34K ﹤0.01% 1294

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIBC World Markets's TSHA Position: Q4 2025 in Review

CIBC World Markets opened a new position in Taysha Gene Therapies (TSHA) in Q4 2025: 14,612 shares worth $80.4K. The stake represents ﹤0.01% of the portfolio and ranks #1181 among its holdings. This is a return to the name: CIBC World Markets previously reported a position in TSHA as recently as Q2 2025.

CIBC World Markets first reported a position in TSHA in Q4 2024 and has held it in 4 quarters since. 195 funds tracked by Wall St. Rank hold TSHA as of Q4 2025.

  • CIBC World Markets held 14,612 shares of Taysha Gene Therapies worth $80.4K as of Q4 2025.
  • Taysha Gene Therapies was a new CIBC World Markets position in Q4 2025.
  • Taysha Gene Therapies made up ﹤0.01% of CIBC World Markets's portfolio in Q4 2025, its #1181 holding.
  • CIBC World Markets first reported a position in Taysha Gene Therapies in Q4 2024 and has held it in 4 quarters since.
  • 195 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2025.

Based on CIBC World Markets's 13F filing for Q4 2025, filed 12 Feb 2026.